ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
update
/
details

Genentech Acquires Regor’s CDK Inhibitors and AntlerA Therapeutics to Bolster Oncology and Ophthalmology Pipeline

NextEdge Admin

01 Oct 2024

2 min 4 sec

AntlerA Therapeutics,Regor Pharmaceuticals,Roche

Genentech has secured Regor Pharmaceuticals' portfolio of CDK inhibitors with an $850 million upfront payment, acquiring a promising breast cancer candidate that has shown single-agent efficacy in patients unresponsive to current treatments. Announced at Roche's Pharma Day, the deal also includes Roche’s acquisition of AntlerA Therapeutics, a biotech specializing in Wnt signaling.

Regor’s next-generation CDK inhibitor, RGT-419B, demonstrated strong phase 1a results in hormone receptor (HR)-positive, HER2-negative breast cancer patients who previously progressed on CDK4/6 inhibitors. The drug, designed to overcome resistance and reduce toxicity, achieved a 28.6% confirmed partial response rate, with no severe adverse events. Regor will continue managing the phase 1 trials, after which Genentech will take over further development and commercialization.

This acquisition complements Roche’s broader push into HR-positive breast cancer, which makes up 70% of cases. Roche is also developing giredestrant, a selective endocrine receptor degrader, and inavolisib, a PI3K inhibitor, which it plans to combine with CDK inhibitors. With the addition of Regor’s CDK portfolio, Roche gains proprietary inhibitors to enhance its treatment offerings.

Additionally, Roche’s acquisition of AntlerA Therapeutics strengthens its focus on ophthalmology, particularly targeting neovascular age-related macular degeneration and diabetic macular edema. These moves align with Roche’s strategic goal of delivering transformative medicines in areas of high societal impact.